Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?
| Title | Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable? |
| Publication Type | Journal Article |
| Year of Publication | 2020 |
| Authors | Koufakis, T., Metallidis S., Zebekakis P., Ajjan R. A., & Kotsa K. |
| Journal | J Diabetes Sci Technol |
| Volume | 14 |
| Issue | 4 |
| Pagination | 745-747 |
| Date Published | 2020 Jul |
| ISSN | 1932-2968 |
| Keywords | Betacoronavirus, Cardiovascular Diseases, Coronavirus Infections, Cytokines, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis, Humans, Metformin, Oxidative Stress, Pandemics, Pneumonia, Viral, Prognosis, Risk Assessment, Risk Factors, Sodium-Glucose Transporter 2 Inhibitors |
| DOI | 10.1177/1932296820932155 |
| Alternate Journal | J Diabetes Sci Technol |
| PubMed ID | 32486846 |
| PubMed Central ID | PMC7673172 |
